PEACCEL

Quantum-ready, AI-native drug-discovery platform with first-in-class anti-infective & metabolic peptides, $8.7m+ non-dilutive funding locked in, and a patent estate already battle-tested against a US major player - now ready for scale-up. Raising funds: $50M Series A Use: - scale the AI + Quantum engine - secure multiple strategic partnerships - and advance 2 lead drug to IND-readiness. PEACCEL is pioneering AI- and Quantum-driven peptide and protein design. Its proprietary innov’SAR™ platform integrates generative AI, reinforcement learning, and early Quantum machine learning to engineer high-value biologics with exceptional speed and precision. The company targets two major unmet medical needs: (1) antimicrobial resistance, and (2) cardio-metabolic disease through peptides entering pre-clinical development. Powered by Google Cloud and recognized by NVIDIA as an “AI Start-Up to Watch”. PEACCEL demonstrated a quantum advantage up to 14 qubits for drug toxicity prediction.